Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations
Journal for ImmunoTherapy of Cancer · 2025-06 · 13 (6) · e011271
DOI: 10.1136/jitc-2024-011271 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 08.06.2025. Verfasst von Linda Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Westmead Institute for Medical Research, Westmead, New South Wales, Australia linda.wu@sydney.edu.au. Hauptthemen laut MEDLINE: Hyperglycemia, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have an expanding role in the management of numerous cancers. Hyperglycaemia is commonly seen in patients treated with ICIs. However, the differential diagnosis for hyperglycaemia is broad, and incorrect diagnosis can have serious consequences. Herein we review the available literature on causes of hyperglycaemia in ICI treated patients and expert guidelines on management and provide an updated synthesis of expert multidisciplinary recommendations. Our key recommendations are as follows: Intensity of screening for hyperglycaemia should be based on a patient’s risk level, including assessment of factors such as corticosteroid use, pre-existing diabetes, baseline HbA1c and fasting blood glucose levels (BGL). People with new onset hyperglycaemia should undergo initial assessment to determine severity and aetiology, including bedside capillary BGL, and formal bloods including lipase, C-peptide with matching glucose, electrolytes and renal function and in some cases type 1 diabetes autoantibodies. People with BGL >15mmol/L (or those receiving SGLT2 inhibitors with BGL >10mmol/L) should additionally have ketones measured. Patients with a high risk of diabetic ketoacidosis (BGL>15 mmol/L, ketones >2 mmol/L) and/or risk of hyperosmolar hyperglycaemic state (BGL persistently >20 mmol/L or reading ‘HI’) should be referred directly to hospital for emergency assessment and management. Further management of hyperglycaemia should be tailored to the underlying cause(s).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Westmead Institute for Medical Research, Westmead, New South Wales, Australia linda.wu@sydney.edu.au.
- Westmead Hospital, Westmead, New South Wales, Australia.
- Royal North Shore Hospital, St Leonards, New South Wales, Australia.
- Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.
- Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia.
- Mater Hospital, North Sydney, New South Wales, Australia.
Zitieren
APA
Wu, L., Tsang, V., Clifton-Bligh, R., Carlino, M. S., Tse, T., Huang, Y., Oatley, M., Cheung, N. W., Long, G. V., Menzies, A. M., & Gunton, J. (2025). Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations. Journal for ImmunoTherapy of Cancer, 13(6), e011271. https://doi.org/10.1136/jitc-2024-011271
Vancouver
Wu L, Tsang V, Clifton-Bligh R, Carlino MS, Tse T, Huang Y, et al. Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations. Journal for ImmunoTherapy of Cancer. 2025;13(6):e011271. doi:10.1136/jitc-2024-011271
BibTeX
@article{Wu2025,
author = {Wu, Linda and Tsang, Venessa and Clifton-Bligh, Roderick and Carlino, Matteo S and Tse, Tim and Huang, Yiting and Oatley, Meredith and Cheung, Ngai Wah and Long, Georgina V and Menzies, Alexander Maxwell and Gunton, Jenny},
title = {Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {6},
pages = {e011271},
doi = {10.1136/jitc-2024-011271}
}
EUVIMED